ID
32071
Description
Study ID: 103992 Clinical Study ID: 103992 Study Title: Evaluate immunogenicity, reactogenicity & safety of 2 doses of GSK Biologicals’ oral live attenuated HRV vaccine (RIX4414 at 106.5 CCID50) when given concomitantly with OPV versus given alone (HRV vaccine dose given 15 days after the OPV dose) in healthy infants in Bangladesh Patient Level Data: Study Listed on ClinicalStudyDataRequest.com Clinicaltrials.gov Identifier: NCT00139334 https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1 Sponsor: GlaxoSmithKline Collaborators: N/A Phase: Phase 2 Study Recruitment Status: Completed Generic Name: Rotavirus Vaccine Trade Name: Rotarix Study Indication: Haemophilus influenzae type b; Neisseria Meningitidis This form is for documentation of demographics, informed consent and randomization/treatment number. To be filled in at Visit 1. Timing: Day 0 Age: 6 weeks +/- 1 week
Link
https://clinicaltrials.gov/ct2/show/NCT00139334?term=NCT00139334&rank=1
Keywords
Versions (2)
- 10/16/18 10/16/18 - Sarah Riepenhausen
- 10/16/18 10/16/18 - Sarah Riepenhausen
Copyright Holder
GlaxoSmithKline
Uploaded on
October 16, 2018
DOI
To request one please log in.
License
Creative Commons BY-NC 3.0
Model comments :
You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.
Itemgroup comments for :
Item comments for :
In order to download data models you must be logged in. Please log in or register for free.
GSK Biologicals' oral HRV vaccine given with OPV in infants NCT00139334
Demographics and Administrative Data
- StudyEvent: ODM
Similar models
Demographics and Administrative Data
- StudyEvent: ODM
C0600091 (UMLS CUI [1,2])
C0205394 (UMLS CUI [1,2])